Analysis Pharmacovigilance

FTC's bid to block Covetrus-MWI puts veterinary distribution, and PV information flow, in focus

The US suit against a $3.5bn merger of the two largest vet distributors is an antitrust case, but animal-health PV teams should check how safety information moves through the channel.

VigiEye editorial · Mon 16 Nov 2026

What happened

On 13 November 2026 the US Federal Trade Commission sued to block Covetrus's $3.5bn acquisition of veterinary distributor MWI. The agency says the deal would combine the two largest distributors to veterinary clinics and would raise prices and erode service quality across animal health supply.

The records do not say how the court case will proceed, whether the parties will contest it or amend the deal, or what timetable applies. Those points are not yet known. The FTC's announcement is framed around competition and pricing, and nothing in the record refers to pharmacovigilance.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →